Back to Journals » Therapeutics and Clinical Risk Management » Volume 12

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]

Authors Sechi A, Dardis A, Bembi B

Received 8 March 2016

Accepted for publication 8 March 2016

Published 7 July 2016 Volume 2016:12 Pages 1083—1084

DOI https://doi.org/10.2147/TCRM.S108027

Sechi A, Dardis A, Bembi B. Ther Clin Risk Manag. 2016; 12:53–58.

On page 57, left column, line 22, the text “patients who result in poor metabolizers should not be treated with this drug” should have been “patients who result in CYP2D6 ultra-rapid metabolizers or who are indeterminate metabolizers should not be treated with this drug”.

Read the original article



Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Profile of eliglustat tartrate in the management of Gaucher disease

Sechi A, Dardis A, Bembi B

Therapeutics and Clinical Risk Management 2016, 12:53-58

Published Date: 11 January 2016